Zanubrutinib-Obinutuzumab could double PFS in patients with follicular lymphoma
Time : 23rd of June 2022 01:59:13 PM
,
The overall response rate in patients who received Zanubrutinib-Obinutuzumab (ZO) was 68.3%, compared to 45.8% in those who received only Obinutuzumab (O), as per a study. Also, the complete response rate was 37.2% with ZO therapy than 19.4% with only O therapy. The median progression-free survival with ZO therapy was 27.4 months compared to 11.2 months with only O therapy.
European Hematology AssociationTags
zanubrutinib, obinutuzumab, follicular lymphomaRecent Posts
China: Announcement of the zero-Covid policy lasting for 5 years alarms Beijing
28th of June 2022 04:09:19 PM
28th of June 2022 04:09:19 PM
BioGX and Cepheid announce collaboration to generate monkeypox PCR test
28th of June 2022 03:57:48 PM
28th of June 2022 03:57:48 PM
AST issues statement post-overturning decision of Roe V. Wade in the US
28th of June 2022 03:09:15 PM
28th of June 2022 03:09:15 PM
Guidelines on the management of cirrhosis-related bleeding and thrombosis: EASL
28th of June 2022 02:56:42 PM
28th of June 2022 02:56:42 PM
How many people are consuming immune-boosting micro-organisms in their diet?
28th of June 2022 02:44:32 PM
28th of June 2022 02:44:32 PM
Prenatal antibiotic use could be linked to an increased risk of asthma in children
28th of June 2022 01:57:07 PM
28th of June 2022 01:57:07 PM
CDC issues new details on the unknown cause of hepatitis in children in the US
28th of June 2022 01:01:15 PM
28th of June 2022 01:01:15 PM
